Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds

Journal of Biomolecular Screening

Volumn 13, Issue 8, 2008, Pages 795-803

  Hawes, Jessica J ^a   Nerva, John D ^a   Reilly, Karlyne M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Astrocytoma; E2F1; Luciferase; Nf1; p53

Indexed keywords

ANTINEOPLASTIC AGENT; NEUROFIBROMIN; PROTEIN P53; PROTEIN TRP 53; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTROCYTE; ASTROCYTOMA; CELL CONTACT; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CAMPTOTHECIN; CYTOSTATIC AGENTS; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HUMANS; NOCODAZOLE; REPRODUCIBILITY OF RESULTS;

EID: 51249095826     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108321085     Document Type: Article

References (28)

1. Central Brain Tumor Registry of the United States: Primary Brain Tumors in the United States-Statistical Report. Chicago: Central Brain Tumor Registry of the United States, 2002.
2. Ohgaki H.: Genetic pathways to glioblastomas. Neuropathology 2005 ; 25: 1-7.
3. McLendon RE, Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated ? Cancer 2003 ; 98: 1745-1748.
4. Gilbert MR, Loghin M.: The treatment of malignant gliomas. Curr Treat Options Neurol 2005 ; 7: 293-303.
5. Ichimura K., Bolin MB, Goike HM, Schmidt EE, Moshref A., Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000 ; 60: 417-424.
6. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD,, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994 ; 54: 1324-1330.
7. Watanabe K., Sato K., Biernat W., Tachibana O., von Ammon K., Ogata N.,, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997 ; 3: 523-530.
8. von Deimling A., Eibl RH, Ohgaki H., Louis DN, von Ammon K., Petersen I.,, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992 ; 52: 2987-2990.
9. Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996 ; 17: 1187-1198.
10. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW,, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997 ; 275: 343-349.
11. Huson S., Hughes R.: The Neurofibromatoses: A Pathogenetic and Clinical Overview. London: Chapman & Hall Medical, 1994.
12. Martin GA, Viskochil D., Bollag G., McCabe PC, Crosier WJ, Haubruck H.,, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990 ; 63: 843-849.
13. Cichowski K., Shih TS, Schmitt E., Santiago S., Reilly K., McLaughlin ME,, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999 ; 286: 2172-2176.
14. Vogel KS, Klesse LJ, Velasco-Miguel S., Meyers K., Rushing EJ, Parada LF: Mouse tumor model for neurofibromatosis type 1. Science 1999 ; 286: 2176-2179.
15. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000 ; 26: 109-113.
16. Uhrbom L., Nerio E., Holland EC: Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004 ; 10: 1257-1260.
17. Sanchez JF, Sniderhan LF, Williamson AL, Fan S., Chakraborty-Sett S., Maggirwar SB: Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol 2003 ; 23: 4649-4662.
18. Almond B., Hawkins E., Stecha P., Garvin D., Paguio A., Butler B.,, et al. A New Luminescence: Not Your Average Click Beetle. 2003. Retrieved from www.promega.com
19. Gammon ST, Leevy WM, Gross S., Gokel GW, Piwnica-Worms D.: Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. Anal Chem 2006 ; 78: 1520-1527.
20. Uht RM, Amos S., Martin PM, Riggan AE, Hussaini IM: The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene 2007 ; 26: 2885-2893.
21. Ahn N., Tolwinski NS, Hsiao K., Goueli SA: U0126: An Inhibitor of MKK/ERK Signal Transduction in Mammalian Cells. Madison, WI: Promega Corporation, 1999.
22. Barnouin K., Dubuisson ML, Child ES, Fernandez de Mattos S., Glassford J., Medema RH,, et al. H202 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem 2002 ; 277: 13761-13770.
23. Yamada HY, Gorbsky GJ: Cell-based expression cloning for identification of polypeptides that hypersensitize mammalian cells to mitotic arrest. Biol Proced Online 2006 ; 8: 36-43.
24. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
25. Assay Guidance Manual Version 4.1. 2005. Retrieved from http://www.ncgc.nih.gov/guidance/manual_toc.html
26. Klautke G., Schutze M., Bombor I., Benecke R., Piek J., Fietkau R.: Concurrent chemoradiotherapy and adjuvant chemotherapy with topotecan for patients with glioblastoma multiforme. J Neurooncol 2006 ; 77: 199-205.
27. Adwankar MK, Khandalekar DD, Chitnis MP: Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cisdiamminedichloroplatinum and vincristine. Oncology 1984 ; 41: 370-373.
28. Jolad SD, Hoffmann JJ, Torrance SJ, Wiedhopf RM, Cole JR, Arora SK,, et al. Bouvardin and deoxybouvardin, antitumor cyclic hexapeptides from Bouvardia ternifolia (Rubiaceae). J Am Chem Soc 1977 ; 99: 8040-8044.